Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial setbacks and trimmed the top end of guidance for its life sciences unit.
Source link
lol
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial setbacks and trimmed the top end of guidance for its life sciences unit.
Source link
lol